By: Mike Basset From: medpagetoday.com About 110,000 new cases of leptomeningeal disease (metastases of cerebrospinal fluid or the thin membranes that surround the brain and spinal cord) are diagnosed each year in the U.S., with the incidence varying among cancer types. Among breast cancer patients, incidence ranges between 5% and 8% . Patients with HER2-positive status are at particularly high …
A step-by-step guide to physical and visual breast exams
Early detection plays a key role in protecting your health when it comes to breast cancer (or any type of cancer). Screening mammograms should start at age 40, but recommendations may vary across organizations and depending on factors, including whether you have a gene mutation, denser breast tissue, or a family history of breast cancer. Here’s how to perform a …
FDA Green-Lights Five New Treatment Options for Breast Cancer
By: Liz Highleyman From: cancerhealth.com The Food and Drug Administration (FDA) recently approved several new therapies for breast cancer, including for patients with metastatic (Stage IV) cancer and hard-to-treat triple-negative breast cancer (TNBC). Because treatment is continually evolving, it is often possible to move on to new medications if current ones stop working. Breast cancer, classified by the type of …
Gedatolisib Combinations Nearly Double PFS in PIK3CA-Mutant Breast Cancer
By:Sara A. Hurvitz, MD, Sabrina Seran From: targetedonc.com On July 14, 2026, the FDA approved gedatolisib (Revtorpyk) in combination with fulvestrant (Faslodex), with or without palbociclib (Ibrance), for adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation, based on results from Study 1 of the phase 3 VIKTORIA-1 trial (NCT05501886).1 Gedatolisib is the …
New Breast Cancer Study Offers Hope for Less Swelling
From: breastadvocateapp.com For many women with breast cancer, treatment doesn’t end after the tumor is removed. Decisions about lymph node treatment can have a lasting impact on recovery and quality of life. Now, new research presented at the 15th European Breast Cancer Conference (EBCC 2026) suggests that radiotherapy may help some patients avoid more extensive lymph node surgery while reducing their risk of …
History of Breast Cancer
Breast cancer is the most common cancer in women around the world. It has been widely studied throughout history. In fact, research on breast cancer has helped pave the way for breakthroughs in other types of cancer research. How we treat breast cancer has changed in many ways from the cancer’s first discovery. But other findings and treatments have remained …
What Types of Breast Cancer Have the Highest Recurrence Rates?
From: healthline.com Although the type of breast cancer you have plays a large role in its recurrence, it’s not the only factor.Breast cancer variables such as tumor size and stage at diagnosis can also influence your risk. Personal factors such as your age and your weight can affect your risk as well. In this article, we take a closer look …
Mapping the Storm: Researchers Explore How Hurricanes Disrupt Cancer Care
By: Pat Carragher From :moffitt.org When Hurricane Milton swept across Florida in 2024, it left hundreds of thousands without power, damaged homes and disrupted daily life across much of the state. Among those affected were Moffitt Cancer Center researcher Jacob Kresovich, PhD, and the USF College of Public Health environmental epidemiologist Catherine Bulka, PhD, whose family spent several days without electricity after the storm. The experience sparked …
Behind the Gedatolisib FDA Approval: An Investigator’s Perspective on HR+ Breast Cancer
By: Erica Stringer-Reasor, MD From: targetedonc.com The FDA has approved gedatolisib (Revtorpyk), the first dual PI3K/mTOR pathway inhibitor, for patients with hormone receptor–positive, HER2-negative advanced breast cancer who lack a PIK3CA mutation—a group representing roughly 35% to 40% of this population that has had limited targeted treatment options after first-line CDK4/6 inhibitor therapy fails. The drug is approved in combination …
How Inherited BRCA Mutations Shape Breast Cancer’s Genomic Behavior and Point Toward a New Treatment Paradigm
By:Sabrina Serani, Pedram Razavi, MD, PhD From: targetedonc.com Germline mutations in BRCA1 and BRCA2 have long been recognized as breast cancer risk genes, but whether they continue to shape a tumor’s behavior after it develops—and specifically how it responds and eventually resists treatment—has been far less clear. A new study published in Nature by researchers at Memorial Sloan Kettering Cancer …